If our hypothesis is supported by results from the above studies, a novel therapeutic approach deserves to be tested in clinical trials addressing the safety and efficacy of monotherapy with IFN or in combination with ruxolitinib in AD. This evidence concerns the gene IFNA1 and Alzheimer disease.